You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,937,225


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,937,225
Title:Topical formulations and uses thereof
Abstract: Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
Inventor(s): Mitra; Ashim K. (Overland Park, KS), Weiss; Sidney L. (Randolph, NJ)
Assignee: SUN PHARMA GLOBAL FZE (Sharjah, AE)
Application Number:15/153,510
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,937,225
Patent Claims: 1. An aqueous clear nanomicellar ophthalmic formulation comprising 0.05-0.5% by weight cyclosporine, a polyalkoxylated alcohol and one or more polymers comprising HCO-40, HCO-60, HCO-80, HCO-100, polyoxyl 35 castor oil or combinations thereof.

2. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein said polymer comprises HCO-40, HCO-60, HCO-80, HCO-100 or combinations thereof.

3. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein said polymer comprises polyoxyl 35 castor oil.

4. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein said polymer is HCO-40.

5. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein said polymer is 0.5-1.5% by weight of the formulation.

6. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein said polymer comprises HCO-40 HCO-60, HCO-80, or combinations thereof and is 0.5-1.5% by weight of the formulation.

7. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein said polyalkoxylated alcohol comprises Octoxynol-40.

8. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein the polyalkoxylated alcohol comprises Octoxynol-40 and is 0.02-4% by weight of the formulation.

9. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein the polyalkoxylated alcohol comprises Octoxynol-40 and is 0.02-0.1% by weight of the formulation.

10. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein the cyclosporine is 0.05-0.2% by weight of the formulation.

11. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein said polymer comprises HCO-40, HCO-60, HCO-80, HCO-100 or combinations thereof; and wherein said polyalkoxylated alcohol is Octoxynol-40.

12. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein said polymer is 0.5-1.5% by weight of the formulation; and said polyalkoxylated alcohol is Octoxynol-40 and is 0.02-0.1% of the formulation.

13. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein said polymer is 0.5-1.5% of the formulation; said polyalkoxylated alcohol comprises Octoxynol-40 and is 0.02-0.1% of the formulation; and the cyclosporine is 0.05-0.2% of the formulation.

14. A method of treating or preventing an ocular disease or condition, said method comprising topically administering an aqueous clear nanomicellar formulation of claim 1.

15. A method of treating or preventing an ocular disease or condition, said method comprising topically administering an aqueous clear nanomicellar formulation of claim 13.

16. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein said formulation provides higher average concentration of cyclosporine in cornea, conjunctiva and sclera in comparison to higher marketed strength.

17. The aqueous clear nanomicellar ophthalmic formulation of claim 1, wherein said formulation demonstrates mean cumulative inflammatory score of less than 2.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.